biotech

Test tubes

Hutchinson China MediTech Prepares for IPO

Hutchinson China MediTech has filed an amended F-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). No pricing details were given in the ...
Read Full Story »
coins

Incyte Underwhelms With Earnings

Incyte Corp. (NASDAQ: INCY) reported its fourth-quarter financial results after the markets closed on Wednesday. The company had $0.29 in earnings per share (EPS) on $243.88 million in revenue, which ...
Read Full Story »
cancer

Syndax Pharma Gears Up for IPO

Syndax Pharmaceuticals has filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO). No pricing details were given in this offering. ...
Read Full Story »
clinical trials

CTI BioPharma Stumbles Over Full Clinical Hold

CTI BioPharma Corp. (NASDAQ: CTIC) has practically become a penny stock overnight following an update from its Investigational New Drug (IND) application for pacritinib. The update basically states that the ...
Read Full Story »
IPO

Proteostasis Therapeutics Closes in on IPO

Proteostasis Therapeutics has filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO). This company expects to price its 3.85 million ...
Read Full Story »
biotech word cloud

Major Biotech Short Interest Continues to Be Mixed

The short interest data are out for the January 29 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
FDA_logo

Adaptimmune Receives Breakthrough Designation From FDA

Adaptimmune Therapeutics PLC (NASDAQ: ADAP) announced that the U.S. Food and Drug Administration (FDA) granted a Breakthrough Therapy designation for the company’s affinity enhanced T-cell therapy targeting NY-ESO in synovial ...
Read Full Story »
ThinkstockPhotos-481735362

Is BioCryst Reaching Crush Depth?

BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) is getting crushed after announcing results from OPuS-2 for the treatment of hereditary angioedema (HAE) attacks. Unfortunately, the company said that this treatment failed to ...
Read Full Story »
automatic inspection machine

How Analysts Value Gilead Now After Earnings

Gilead Sciences Inc. (NASDAQ: GILD) reported fourth-quarter financial results on Tuesday. As a result, analysts weighed in on this biotech giant and in what direction it might go next. The ...
Read Full Story »
biotech word cloud

Top 4 BioPharma Movers of the Week

Over the past week, a few biotech companies made absolutely massive runs, either up and down. In the past year, the health care sector was on fire from positive trials, ...
Read Full Story »
graph

Why TherapeuticsMD Could Still Rise Almost 200%

TherapeuticsMD Inc. (NYSE: TXMD) is a very speculative women's health care company. Its shares were given heavier attention on Thursday after an analyst report suggested that the stock could have ...
Read Full Story »
IPO

Therapure Biopharma Postpones IPO

The initial public offering (IPO) market has grown cold as global markets have been sliding in 2016, and many companies are choosing to postpone their IPOs for more favorable market ...
Read Full Story »
automatic inspection machine

Will Sinovac Go Through With This Buyout?

Sinovac Biotech Ltd. (NASDAQ: SVA) was riding high early Thursday morning, following the offer for a potential buyout, but it looks like this company doesn’t want to take the bait. ...
Read Full Story »
Test tubes

Gilead Rises on Solid HCV Sales and Earnings Beat

Gilead Sciences Inc. (NASDAQ: GILD) reported fourth-quarter financial results after the markets closed on Tuesday. The company had $3.32 in earnings per share (EPS) on $8.51 billion in revenue, versus ...
Read Full Story »
automatic inspection machine

What Expect From Gilead Earnings

Gilead Sciences Inc. (NASDAQ: GILD) is set to release its fourth-quarter earnings report after the markets close on Tuesday. Thomson Reuters consensus estimates call for $3.00 in EPS on $8.13 ...
Read Full Story »